statements

The stock has been placed in Additional Surveillance Measure (ASM) list LTASM - IV.

Titan Bio-Tech Ltd.

BSE: 524717

Sector: Chemicals

Industry Group: Chemicals & Petrochemicals

Industry: Specialty Chemicals

416.90-2.1 (-0.50%)

27 Jul, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Titan Bio-Tech Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	22.52	27.08	39.13	40.32	45.77	52.74	57.37	64.91	79.44	142.24	123.55	144.00	164.07	156.45	206.19
Cost of Operating Revenue	15.49	17.99	26.76	26.08	34.72	39.28	32.71	34.41	41.15	66.79	70.90	85.96	94.52	90.88	101.12
Gross Profit	7.03	9.09	12.37	14.24	11.05	13.46	24.67	30.50	38.29	75.45	52.65	58.04	69.55	65.57	105.07
Gross Margin	31.2	33.6	31.6	35.3	24.1	25.5	43.0	47.0	48.2	53.0	42.6	40.3	42.4	41.9	51.0
Total Operating Expenses	20.70	24.82	36.93	37.27	42.68	48.19	51.33	57.70	67.76	98.33	94.65	117.08	133.12	135.19	172.51
Operating Profit	1.82	2.25	2.20	3.04	3.09	4.55	6.04	7.21	11.68	43.91	28.90	26.92	30.95	21.26	33.68
Operating Margin	8.1	8.3	5.6	7.6	6.8	8.6	10.5	11.1	14.7	30.9	23.4	18.7	18.9	13.6	16.3
Financing Income/(Expense) - Net	-0.10	-0.36	-0.24	-0.99	-0.99	-1.48	-2.39	-2.29	-2.34	-1.67	-0.76	-0.70	-1.08	-0.29	-0.91
Profit before Taxes	1.85	1.98	2.23	2.45	2.65	3.35	4.10	5.54	10.40	42.71	28.97	28.12	31.53	24.37	38.17
Income Taxes	0.61	0.67	0.74	0.82	0.88	1.17	1.43	1.63	2.57	11.00	7.28	7.09	7.87	6.10	10.73
Profit after Tax	1.24	1.31	1.49	1.63	1.77	2.18	2.54	3.52	7.07	30.34	21.68	24.84	24.85	21.53	29.89
PAT Margin	5.5	4.8	3.8	4.0	3.9	4.1	4.4	5.4	8.9	21.3	17.6	17.3	15.1	13.8	14.5
EPS - Basic - ex Extraordinary Items	0.35	0.37	0.42	0.42	0.46	0.56	0.66	0.85	1.71	7.34	5.25	6.01	6.01	5.21	7.23
EPS - Diluted - ex Extraordinary Items	0.35	0.37	0.42	0.42	0.46	0.56	0.66	0.85	1.71	7.34	5.25	6.01	6.01	5.21	7.23
EBIT	1.82	2.25	2.20	3.04	3.09	4.55	6.04	7.21	11.68	43.91	28.90	26.92	30.95	21.26	33.68
EBITDA	2.18	2.61	3.02	3.88	3.86	5.36	6.97	8.92	13.48	46.13	31.27	29.52	34.28	25.43	38.60
EBITDA Margin	9.7	9.7	7.7	9.6	8.4	10.2	12.2	13.7	17.0	32.4	25.3	20.5	20.9	16.3	18.7

Balance Sheet

Abridged

Understanding Balance Sheet

Titan Bio-Tech Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	11.54	11.75	16.52	21.26	23.78	29.54	29.27	35.14	44.20	58.83	63.76	68.31	72.17	79.04	85.24
Long-Term Investments	0.23	0.21	0.25	0.28	0.45	0.47	0.54	0.57	0.61	-	0.16	5.06	14.72	10.15	65.19
Property Plant & Equipment - Net	9.75	10.33	11.13	11.97	15.81	21.94	26.80	28.92	31.13	33.79	38.51	49.10	54.47	58.85	63.25
Total Non-Current Assets	10.00	10.55	11.38	12.25	16.27	22.64	27.54	29.59	31.84	41.89	44.34	66.21	84.41	95.67	128.64
Total Assets	21.54	22.30	27.90	33.51	40.05	52.18	56.81	64.73	76.04	100.72	108.09	134.52	156.58	174.71	213.88
Total Current Liabilities	6.64	5.69	8.38	10.47	12.66	12.25	11.01	15.78	20.43	19.28	16.95	20.35	19.13	17.74	25.96
Long Term Debt	0.97	2.01	3.91	2.19	4.28	15.17	17.87	13.17	11.55	6.25	2.19	1.43	1.15	0.42	1.77
Total Non-Current Liabilities	1.13	2.15	4.18	2.56	4.74	15.79	20.25	15.19	14.06	8.96	4.90	4.25	4.00	3.57	6.37
Total Liabilities	7.77	7.84	12.56	13.03	17.40	28.05	31.26	30.97	34.49	28.24	21.85	24.60	23.13	21.30	32.34
Total Shareholders' Equity	13.77	14.47	15.34	20.47	21.53	23.01	24.36	32.18	39.19	68.76	86.24	109.91	133.45	153.40	181.55
Minority Interest	-	-	-	-	1.13	1.13	1.19	1.58	2.35	3.72	-	-	-	-	-
Total Equity	13.77	14.47	15.34	20.47	22.65	24.14	25.55	33.76	41.55	72.48	86.24	109.91	133.45	153.40	181.55
Total Liabilities & Equity	21.54	22.30	27.90	33.51	40.05	52.18	56.81	64.73	76.04	100.72	108.09	134.52	156.58	174.71	213.88

Cash Flow

Abridged

Understanding Cash Flow Statement

Titan Bio-Tech Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	1.60	1.66	2.44	2.58	2.65	3.15	4.11	6.27	10.25	34.32	24.50	23.56	27.25	22.87	35.90
Working Capital - Increase/(Decrease)	-0.35	-0.54	-3.28	-5.37	1.16	-4.50	-4.60	-3.09	-6.47	-16.90	-3.33	-3.13	-7.28	-3.55	-6.40
Net CF from Operating Activities	1.25	1.12	-0.84	-2.79	3.81	-1.34	-0.49	3.18	3.78	17.41	21.17	20.43	19.98	19.32	29.51
Capital Expenditures - Net	1.92	0.94	1.62	1.68	4.61	7.17	5.76	4.45	4.01	4.86	13.68	13.17	8.71	8.57	9.29
Net CF from Investing Activities	-3.09	-0.80	-1.96	-3.04	-4.96	-8.39	-5.57	-4.11	-2.21	-4.86	-16.44	-20.73	-20.30	-9.87	-34.41
Dividends Paid - Cash - Total	-	0.62	0.62	0.70	0.70	0.70	0.70	-	-	0.83	1.24	1.24	1.49	1.65	1.65
Stock - Issuance/(Retirement) - Net	3.00	-	-	4.20	-	-	-	4.20	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-1.02	1.87	3.41	0.72	3.70	11.05	3.32	-2.13	-1.61	-8.11	-1.99	-0.42	-0.21	-5.51	2.91
Net Cash Flow from Financing Activities	1.98	1.25	2.79	4.22	3.00	10.35	2.62	2.07	-1.61	-8.93	-3.23	-1.66	-1.70	-7.16	1.26
Free Cash Flow to Equity	-1.68	2.05	0.95	-3.75	2.89	2.54	-2.93	-3.40	-1.84	4.44	5.50	6.84	11.06	5.24	23.12
Free Operating CF net dividend	-0.66	-0.43	-3.07	-5.17	-1.50	-9.21	-6.95	-1.27	-0.23	11.72	6.25	6.02	-1.20	8.22	18.54
Free Operating CF	-0.66	0.19	-2.46	-4.48	-0.81	-8.51	-6.25	-1.27	-0.23	12.55	7.49	7.26	0.29	9.88	20.19

Business Segment Analysis

FY End:

Mar 25

Titan Bio-Tech Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Biological goods (100.0%)₹ 9.44 Cr

Revenue / Sales

Biological goods (100.0%)₹ 156.45 Cr

Assets

Biological goods (100.0%)₹ 174.71 Cr

Operating Income

Biological goods (100.0%)₹ 21.26 Cr

Regional Segment Analysis

FY End:

Mar 25

Titan Bio-Tech Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Domestic (65.5%)₹ 102.55 CrOverseas (34.5%)₹ 53.90 Cr

Historical Segment Analysis

Track how Titan Bio-Tech Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2023 Mar 31	2024 Mar 31	2025 Mar 31

Biological goods	13	20	9

Frequently Asked Questions

What is the revenue of Titan Bio-Tech Ltd.?

The latest trailing twelve month revenue of Titan Bio-Tech Ltd. is ₹ 206.19 Cr, reflecting a 1-year growth of 31.79% and a 3-year CAGR of 12.71%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Titan Bio-Tech Ltd.?

The latest trailing twelve month net profit (PAT) of Titan Bio-Tech Ltd. is ₹ 29.89 Cr, with a 3-year earnings CAGR of 6.34%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Titan Bio-Tech Ltd.?

The trailing twelve month EBITDA of Titan Bio-Tech Ltd. is approximately ₹ 33.68 Cr (based on an operating margin of 16.33%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Titan Bio-Tech Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Titan Bio-Tech Ltd. is 7.23. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Titan Bio-Tech Ltd.?

The debt-to-equity ratio of Titan Bio-Tech Ltd. stands at 0.03. The interest coverage ratio is 36.85x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Titan Bio-Tech Ltd.?

The estimated book value per share of Titan Bio-Tech Ltd. is 43.94 (derived from a P/B ratio of 9.49 and market price of ₹ 416.90), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Titan Bio-Tech Ltd.?

The trailing twelve month operating cash flow of Titan Bio-Tech Ltd. is ₹ 29.51 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Titan Bio-Tech Ltd. report consolidated or standalone financials?

Titan Bio-Tech Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.